This week: endocrinologist Dr. Abud Bakri walked Huberman through the peptide landscape — BPC-157, GHK-Cu, thymosin beta-4, and the GLP-1 agonists — separating the compounds with human trial data from the ones running on animal studies and anecdote. And Nolan Williams returned in Essentials with the SAINT neuromodulation protocol for treatment-resistant depression.

GM.

The episode most people need to hear before they order anything is Abud Bakri on Huberman. The peptide market has exploded — BPC-157 for healing, GHK-Cu for skin, thymosin beta-4 for tissue repair — and the gap between what's promoted and what's proven is wider than in almost any other health category. Bakri walked through each compound and graded the evidence. The result is humbling.

⏱ ~5 min read

Two conversations this week sat at opposite ends of the evidence spectrum. One: the peptide space, where compounds with strong animal data but minimal human trial evidence are being used by millions. Two: the SAINT neuromodulation protocol, where a Stanford team ran rigorous RCTs and achieved an 80% remission rate in treatment-resistant depression. The contrast is instructive.

The thread this week: the distance between 'promising' and 'proven' is measured in human trials — and most of what the wellness market sells lives on the wrong side of that line.

<5
The approximate number of popular performance peptides with published, peer-reviewed human RCT data supporting their marketed claims.

Bakri structured the peptide landscape into evidence tiers. Tier 1 (strong human RCT data): GLP-1 receptor agonists (semaglutide, tirzepatide) — well-studied, FDA-approved, with large Phase III trials. Tier 2 (some human data, mostly observational or small trials): growth hormone secretagogues like ipamorelin and CJC-1295 — used clinically in some contexts but without the RCT evidence base of GLP-1s. Tier 3 (animal data only, no rigorous human trials): BPC-157, thymosin beta-4, GHK-Cu — the compounds most aggressively marketed in the wellness space.

The BPC-157 situation is representative. Dozens of animal studies show remarkable healing properties — tendon repair, gut healing, neuroprotection. But as of 2026, there are zero published, peer-reviewed, placebo-controlled human RCTs for BPC-157. Every human use case is anecdotal. Bakri's position: the animal data is genuinely interesting, but animal-to-human translation in pharmacology fails more often than it succeeds.

Bakri also raised safety concerns that the peptide community rarely discusses. Grey-market peptides are manufactured in unregulated facilities, often in China. Purity, sterility, and dosing accuracy are unverified. A 2024 FDA analysis of grey-market peptide samples found that 15–30% contained contaminants, incorrect doses, or different compounds than labelled.

The peptide that 'works for everyone on Reddit' may work. It may not. The problem is that without human trials, no one — including the person selling it — actually knows.

Dr. Abud Bakri on Huberman Lab · May 2026

The peptide evidence ladder — most popular compounds are on the bottom rung
Abud Bakri grades every major peptide by evidence tier and explains what you're risking with grey-market sourcing.
Dr. Abud Bakri · Huberman Lab · May/June 2026

Bakri is an endocrinologist who works with peptides clinically, which makes his caution more credible than an outsider's criticism. He's not anti-peptide. He's pro-evidence. The conversation with Huberman is the most balanced assessment of the peptide market currently available in podcast form.

🎙️ Listen → Huberman Lab, Dr. Abud Bakri, May/June 2026

Bakri gives you the evidence gradient. The SAINT protocol gives you what rigorous evidence looks like. The gap is the story.

The SAINT neuromodulation protocol Nolan Williams developed at Stanford sits at the opposite end of the evidence spectrum from grey-market peptides. SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) uses MRI-guided transcranial magnetic stimulation delivered in a concentrated protocol — multiple sessions per day over five days — targeting the specific prefrontal region that is functionally disconnected from the anterior cingulate in each individual patient.

The results are remarkable: in a double-blind RCT published in the American Journal of Psychiatry, 79% of patients with treatment-resistant depression achieved remission within five days. The effect was durable at one-month follow-up. This is not a promising animal study. It's a rigorous human trial with an active control and blinded assessment. That's the standard.

The contrast with the peptide market is instructive. BPC-157 has compelling animal data and widespread anecdotal human use. SAINT has RCT data showing 79% remission in a population where nothing else worked. Both are 'promising.' Only one has actually been proven. The difference is the human trial — the expensive, slow, rigorous step that separates hope from evidence.

Bakri's meta-point: the wellness market's tolerance for pre-clinical evidence is dramatically higher than medicine's, and that gap creates real risk. Being excited about a compound is fine. Using it without acknowledging the evidence tier you're operating at is not. The honest framing is: 'I'm choosing to use something that hasn't been proven in humans, and I accept that risk.' Most peptide users have never been given that framing.

Hope is not evidence. Animal data is not human proof. The difference matters most when you're the one injecting the substance.

P.S. Have you used a peptide? Which one, what for, and what happened? We want real reports — positive, negative, or 'couldn't tell.' Hit reply. Anonymised roundup in a future issue.

What did you think of today's BrainBite?